Copyright
©The Author(s) 2021.
World J Hepatol. Nov 27, 2021; 13(11): 1688-1698
Published online Nov 27, 2021. doi: 10.4254/wjh.v13.i11.1688
Published online Nov 27, 2021. doi: 10.4254/wjh.v13.i11.1688
Table 1 Liver biochemical tests and their respective sites and functions
| Interpretation | Test | Site (s) | Function |
| Hepatocellular integrity | ALT | Hepatocyte (main), cardiac, renal and muscle tissue to smaller extent | Amino acid catabolism. Glutamate and pyruvate production for ATP production |
| AST | Hepatocyte, cardiac, muscle and brain tissue | ||
| LDH | Nonspecific, present widely in the body | Anaerobic glycolysis major enzyme in addition to NADH production. Significant in ischemic hepatitis | |
| Cholestatic pattern | ALP | Hepatobiliary tract, bone, placenta and intestines | Dephosphorylation reactions. Role in bile production |
| GGT | Mainly in hepatobiliary tract, present in multiple other organs (nonspecific as an isolate test) | Aids in identification of elevated ALP of biliary origin | |
| 5’nucleotidase | Nonspecific, present widely in the body | Clinical value in hepatobiliary and cholestatic disease specifically when paired with ALP and GGT | |
| Bilirubin | Serum and liver | End product of heme breakdown. Exists in conjugated and unconjugated form. Elevation in conjugated suggestive of possible cholestasis | |
| Synthetic function | Albumin | Serum | Main protein in the serum, maintains oncotic pressure. Produced by the liver |
| PT/INR | Test to measure extrinsic coagulation pathway | Clotting factors primarily produced in the liver. Helpful however does not reflect true coagulation status |
Table 2 R-value calculation and interpretation
| R value = (ALT ULN ALT)/(ALP ÷ ULN ALP) | |
| R value | Interpretation |
| > 5 | Hepatocellular pattern |
| > 2 but < 5 | Mixed pattern |
| < 2 | Cholestatic pattern |
Table 3 Common condition with abnormal liver biochemical tests
| Condition | AST/ALT | ALP | GGT | Bilirubin | Other |
| Alcoholic hepatitis | ↑↑ AST:ALT > 2 | ↑ | ↑ | ↑ | AST/ALT < 500 |
| NAFLD | -/↑ ALT > AST | -/Mild ↑ | -/Mild ↑ | ↑ If progress to cirrhosis | - |
| Viral hepatitis | ↑↑ In acute/↑ in chronic | ↑ | ↑ | ↑ In chronic | AST:ALT > 1 suggestive of cirrhosis |
| Hemochromatosis | ↑ ALT > AST | ↑ | ↑ | ↑ Higher levels = higher iron load | ↑ Ferritin and transferrin saturation |
| Wilson’s disease | ↑/↑↑↑ AST:ALT > 2.2 in ALF | ↑ | ↑ | ↑ | ALP:Bilirubin < 4 |
| AATD | ↑ AST > ALT | - | - | - | - |
| Celiac disease | ↑ ALT > AST | - | - | - | - |
| Autoimmune hepatitis | ↑↑ | ↑ | ↑ | ↑ | ALP:AST/ALT < 3 |
| DILI | ↑↑/↑↑ | ↑ | ↑ | ↑ | ↑ PT/INR |
| Cholestasis | ↑ | ↑↑ | ↑↑ | ↑ | AST:ALT < 1.5 – ExtrahepaticAST:ALT > 1.5 - Intrahepatic |
Table 4 Non-alcoholic fatty liver disease spectrum
| Non-alcoholic fatty liver disease spectrum | ||
| NAFL | Steatosis changes. No cellular ballooning, hepatocyte inflammation or fibrosis | Prevalence of 25% approximately. Reversible |
| NASH | Steatosis changes. Cellular ballooning and hepatocyte inflammation. No fibrosis | Prevalence of 1.5%-6.45% approximately. Generally irreversible (has been found to be reversible in some patients) |
| NASH related liver cirrhosis | Hepatocyte destruction and fibrosis | Prevalence of 1%-2% approximately. Irreversible |
| Healthy liver ←→ NAFL → NASH → NASH related cirrhosis | ||
- Citation: Kalas MA, Chavez L, Leon M, Taweesedt PT, Surani S. Abnormal liver enzymes: A review for clinicians. World J Hepatol 2021; 13(11): 1688-1698
- URL: https://www.wjgnet.com/1948-5182/full/v13/i11/1688.htm
- DOI: https://dx.doi.org/10.4254/wjh.v13.i11.1688
